Psoriasis

Experts discuss icotrokinra's potential to revolutionize psoriasis treatment with oral therapies, emphasizing efficacy, safety, and patient-centered care at EADV 2025.

At a Case-Based Roundtable event, Cory Rubin, MD, discussed real-world strategies for optimizing systemic therapy in patients with moderate to severe psoriasis.

ORKA-001 by Oruka Therapeutics offers promising yearly dosing for psoriasis, showcasing extended efficacy and safety in early clinical trials.

Christopher Bunick, MD, PhD, urged clinicians to move beyond therapeutic inertia and transition patients to advanced systemic therapies.

Stephanie Alvarez, marketing director of Cognivia, details her experience with psoriasis and why she believes clinical trials should reflect more real-world patients and scenarios.

At Fall Clinical, new findings from the ENCOMPASS study revealed significant unmet needs in psoriasis care, highlighting a strong preference for effective oral therapies among patients and providers.

Bristol Myers Squibb reveals promising data on deucravacitinib's efficacy for psoriatic arthritis and systemic lupus erythematosus, highlighting its potential as a new treatment option.

Benjamin Lockshin, MD, noted long half-life biologics may allow patients to maintain remission with minimal injections.

New data presented at Fall Clinical 2025 reveal that patients in socioeconomically disadvantaged areas are significantly less likely to initiate biologic or small molecule treatments.

New data from Johnson & Johnson's ICONIC-TOTAL study reveals icotrokinra's promising long-term efficacy and safety for treating challenging plaque psoriasis.

Data from Fall Clinical 2025 detailed the results from the phase 2 STRIDE and ongoing open-label extension studies demonstrating the efficacy and safety of envudeucitinib, a selective TYK2 inhibitor.

James Del Rosso, DO; April Armstrong, MD, MPH; Mark Nestor, MD, PhD; Mark Lebwohl, MD; Linda Stein Gold, MD; and Darrell Rigel, MD, MS, presented some of the biggest updates in dermatology to close out the year.

Explore real-world strategies with Leigh Ann Pansch, MSN, FNP-BC, DCNP, for managing psoriasis, emphasizing patient-centered care, and implementing individualized biologic treatment approaches.

Andrew Mastro, MS, PA-C, moderated a recent Dermatology Times Case-Based Roundtable event to present 3 complex cases of moderate to severe psoriasis treated with biologics.

Mark Kaufmann, MD, discusses how patient realities shape psoriasis treatment choices.

Researchers found new patients incurred 40% higher consultation costs due to longer clinician interaction times.

A study reveals ixekizumab's effectiveness in treating mild to moderate plaque psoriasis, showing superior PASI responses and improved long-term outcomes.

Psoriasis complicates wound healing due to systemic inflammation, affecting recovery and requiring tailored clinical approaches for optimal patient outcomes.

Explore real-world psoriasis management insights from Anthony Nuara, MD, PhD, focusing on patient-centered approaches and innovative treatments like tildrakizumab.

Discover the latest IPC consensus on psoriasis severity reclassification, enhancing treatment strategies for better patient outcomes and quality of life.

Spesolimab joins LEO Pharma’s dermatology portfolio to further expand spesolimab’s reach for patients worldwide with generalized pustular psoriasis.

WHO includes adalimumab and ustekinumab for psoriasis, plus sunscreen for albinism, enhancing global skin health and access to essential treatments.

Both treatments were well tolerated, with only mild, self-limiting adverse effects reported.

Phase 3 PROTOSTAR data support new indications, expanding treatment options for children impacted by chronic immune-mediated diseases.

Bristol Myers Squibb expands direct-to-patient pricing for deucravacitinib and apixaban, enhancing access and affordability for patients in need.